This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China. With the 2023 update expanding the list of nonhereditary conditions and rare cancers, its influence is increasing.
CRA’s latest analysis examines how RDC inclusion impacts NRDL pricing, revealing subtle but important implications for price negotiations.
“We are pleased to welcome Phoebe and Chris to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “They are seasoned...
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...
Abhishek Kumar presents his poster titled “Top Trends Affecting the Vaccines Market and their Implications on Access Policy and Public Health...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
